Blair William & Co. IL Has $667,000 Stake in Krystal Biotech, Inc. $KRYS

Key Points

• Blair William & Co. IL has reduced its stake in Krystal Biotech, Inc. by 48.6%, now holding 4,852 shares valued at $667,000.
• Despite a decrease in share price by 2.4%, Krystal Biotech reported better-than-expected earnings with $1.29 earnings per share for the last quarter, surpassing estimates.
• Wall Street analysts maintain a consensus rating of "Moderate Buy" for Krystal Biotech with a price target around $209.00, reflecting optimism about the company's growth prospects.

Blair William & Co. IL decreased its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 48.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,852 shares of the company's stock after selling 4,581 shares during the period. Blair William & Co. IL's holdings in Krystal Biotech were worth $667,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of KRYS. GAMMA Investing LLC lifted its position in Krystal Biotech by 179.3% during the 1st quarter. GAMMA Investing LLC now owns 673 shares of the company's stock worth $121,000 after acquiring an additional 432 shares during the last quarter. Fifth Third Bancorp lifted its position in Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after acquiring an additional 105 shares during the last quarter. Oppenheimer Asset Management Inc. acquired a new position in Krystal Biotech during the 1st quarter worth $229,000. Wealthquest Corp acquired a new position in Krystal Biotech during the 1st quarter worth $347,000. Finally, Perigon Wealth Management LLC lifted its position in Krystal Biotech by 2.4% during the 1st quarter. Perigon Wealth Management LLC now owns 8,491 shares of the company's stock worth $1,531,000 after acquiring an additional 202 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech Stock Down 2.4%

NASDAQ:KRYS opened at $188.33 on Friday. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $207.84. The firm has a market capitalization of $5.45 billion, a PE ratio of 38.28 and a beta of 0.64. The firm has a 50-day moving average price of $159.67 and a 200 day moving average price of $151.38.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The firm had revenue of $96.04 million during the quarter, compared to analyst estimates of $95.42 million. On average, research analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on KRYS. Citigroup reaffirmed a "neutral" rating and set a $166.00 price objective (down previously from $176.00) on shares of Krystal Biotech in a research report on Tuesday, August 5th. HC Wainwright reaffirmed a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a research report on Monday, September 15th. Chardan Capital cut their price objective on shares of Krystal Biotech from $219.00 to $216.00 and set a "buy" rating for the company in a research report on Friday, August 22nd. Bank of America cut their price objective on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Krystal Biotech in a research report on Wednesday, October 8th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Krystal Biotech currently has a consensus rating of "Moderate Buy" and a consensus price target of $209.00.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.